Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EXOZ
STRONG SELLeXoZymes, Inc. · Healthcare · United States · $73M · Avg Vol: $60K/d
0
StockRankGet insider-trade alerts
Q
14
V
22
M
10
P/E (TTM)
—
ROE
-185.8%
D/E
0.8x
Dividend %
—
COMPANY DESCRIPTION
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — |
| EPS | -0.17 | -0.25 | -0.89 | -1.09 | — | -1.15 |
| Shares | 8.1M | 8.1M | 8.4M | 8.4M | +3.4% | 9.3M |
| Debt | 0.6M | 1.6M | 1.4M | 1.2M | 26.9% | 1.2M |
| Equity | 1.4M | -0.4M | 10.4M | 3.4M | 35.3% | — |
| Op CF | -1.3M | -1.2M | -8.5M | -6.5M | — | -6.9M |
| Inv CF | -87.2K | -0.3M | -0.4M | -0.2M | — | — |
| Fin CF | 1.4M | 1.0M | 18.5M | -27.7K | — | — |
Loading 1Y...
PRICE (1Y)-35.9%
SMA 50SMA 200
Close
$4.55
RSI (14)
16.4
52W High
$18.40
From 52W High
0.2%
SCORE BREAKDOWN
Quality
14
ROIC
-220.6%1.8
ROE
-185.8%4.5
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-111.7%1.3
Piotroski
12.3
Int. Cover
—N/A
D/E Ratio
0.76x19.9
Current Ratio
1.32x20.4
Value
22
P/E (TTM)
—N/A
EV/EBITDA
-4.8x25.0
P/FCF
—N/A
P/B
31.1x3.4
P/S
—N/A
Div Yield
—N/A
Momentum
10
52W High %
25%5.3
RS 6M
-69%5.7
SMA 50/200
0.76x13.6
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$73M
P/E (Forward)
—
Gross Margin
0.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EXOZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EXOZ | eXoZymes, Inc.(you) | $73M | 0 | STRONG SELL |
| INO | Inovio Pharmaceuticals, Inc. | $80M | 0 | STRONG SELL |
| RNTX | Rein Therapeutics Inc. | $68M | 2 | STRONG SELL |
| 2257.HK | Sirnaomics Ltd. | $64M | 1 | STRONG SELL |
| ELTX | Elicio Therapeutics, Inc. | $79M | 3 | STRONG SELL |
| CRDF | Cardiff Oncology, Inc. | $64M | 2 | STRONG SELL |
| NTHI | NeOnc Technologies Holdings, Inc. | $89M | 1 | STRONG SELL |
| ESLA | Estrella Immunopharma, Inc. | $62M | 2 | STRONG SELL |
| ANVS | Annovis Bio, Inc. | $71M | 8 | STRONG SELL |
| GANX | Gain Therapeutics, Inc. | $75M | 8 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%